BRF1A

BRF1A is a **cannabinoid (CBD)-enriched product** derived from a specific *Cannabis sativa* chemotype with high cannabidiol (CBD) content. It has shown notable **anti-cancer properties in preclinical studies**, particularly investigated in multiple myeloma (hematologic malignancy) and papillary thyroid carcinoma cell lines. BRF1A suppresses growth and function of IgE- and IgG-producing myeloma cells, reduces cell viability, and regulates several cancer-related pathways: - Suppresses expression of p-IκBα, NF-κB (p65), total NF-κB protein, XBP1u, and XBP1s - Increases gene/protein expression of telomere components and telomerase (hTERT) - Upregulates tumor suppressor gene TP53 and p53 protein - Downregulates oncogenes c-Myc and BCL-2 The proposed primary mechanism is anti-proliferative, pro-apoptotic, and modulation of telomere/telomerase signaling and cancer-relevant transcriptional regulation. BRF1A’s activity is attributed mainly to its cannabinoid composition, and specifically to cannabidiol, but the precise full molecular content is not fully characterized in the public literature. The product has been supplied by the Breslin Research Foundation for preclinical cancer research and has demonstrated dose- and time-dependent anti-tumor effects in vitro[1][2][3][5][7][9].

Other names

BRF1ABRF-1ABRF 1A